HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Organon & Co. (OGN)
29.98  -1.48  (-4.7%) 06-21 03:19
Open: 31.5 High: 31.71
Pre.close: 31.46 Low: 29.96
Volume: 9,608,888 Ave vol: 6,450,676
52w High: 38.75 52w Low: 27.25
MA(50): 33.712 MA(200): 33.712
EPS: P/E Ratio: 0
Company profile
Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers—General
Website: http://www.organon.com
Market Cap (M): 7,589
Shares Out (M): 253
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
Technical analysis
Overall: Neutral
MA: Bullish MACD: Bearish
KDJ: Bullish RSI: Bearish
Target 1: 40.13 Target 2: 45.26
Resist 1: 34.36 Resist 2: 38.75
Support 1: 27.25 Support 2: 22.67
Company key metrics
Revenue per Share: 0
Net Income per Share: 0
Cash per Share: 0
Book Value per Share: 0
Price to Sales: 0
Price to Book Value: 0
Earnings Yield: 0
Dividend Yield: 0
Debt to Equity: 0
Debt to Assets: 0
Financial analysis
Price to Book Value: Neutral
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Neutral
Price to Earnings: Neutral
Debt to Equity: Neutral
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.